Menovo(SH:603538)2021-10-27 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥227,070,437.93, a decrease of 23.73% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥19,040,437.69, reflecting a decline of 45.84% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥16,408,956.10, down 47.65% from the previous year[5]. - The net profit for Q3 2021 was CNY 147,629,427.21, a decrease of 2.1% compared to CNY 151,263,113.19 in Q3 2020[21]. - The operating profit for Q3 2021 was CNY 168,916,010.91, down from CNY 183,313,143.88 in the same period last year, reflecting a decline of 7.6%[20]. - The total comprehensive income for Q3 2021 was CNY 147,764,009.20, slightly lower than CNY 150,824,173.02 in Q3 2020[21]. - The diluted earnings per share for Q3 2021 was CNY 0.87, down from CNY 0.96 in Q3 2020, representing a decrease of 9.4%[22]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥184,056,771.80, a decrease of 19.46% compared to the same period last year[5]. - The cash flow from operating activities for the first nine months of 2021 was CNY 184,056,771.80, down 19.5% from CNY 228,532,174.90 in the previous year[23]. - The company reported a net cash outflow from investing activities of CNY 573,601,552.12 for the first nine months of 2021, compared to a net outflow of CNY 276,977,525.68 in the same period of 2020[24]. - The company’s cash and cash equivalents at the end of Q3 2021 amounted to CNY 248,711,439.05, an increase from CNY 243,752,877.70 at the end of Q3 2020[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,725,683,750.51, an increase of 18.34% from the end of the previous year[5]. - Current assets as of September 30, 2021, totaled RMB 1,608,032,587.97, an increase from RMB 1,199,262,158.26 at the end of 2020, reflecting a growth of 34.1%[15]. - Non-current assets increased to RMB 2,117,651,162.54 as of September 30, 2021, compared to RMB 1,949,016,531.82 at the end of 2020, representing a growth of 8.7%[16]. - Total liabilities amounted to RMB 1,669,932,767.08, compared to RMB 1,355,296,200.86 at the end of 2020, indicating an increase of 23.2%[17]. - The company's equity attributable to shareholders was RMB 1,831,996,255.63, up from RMB 1,582,222,330.35 at the end of 2020, reflecting a growth of 15.7%[17]. Research and Development - The company increased R&D expenses by ¥10,930,000, a year-on-year increase of 82.97%[10]. - Research and development expenses increased to CNY 50,073,150.42, up 41.7% from CNY 35,332,495.30 in Q3 2020[20]. Revenue and Costs - Total operating revenue for the first three quarters of 2021 was RMB 918,703,339.02, a decrease of 3.2% compared to RMB 948,915,031.53 in the same period of 2020[19]. - Total operating costs for the first three quarters of 2021 were RMB 780,731,585.79, down from RMB 785,657,488.60 in the previous year, indicating a slight reduction of 0.3%[19]. - The total revenue from operating activities for the first nine months of 2021 was CNY 838,036,257.86, a decrease of 11.5% compared to CNY 946,483,391.70 in the same period of 2020[23]. Government Support - The company received government subsidies amounting to ¥4,516,394.53 during the reporting period, contributing to its financial performance[9]. - The company acquired Ningbo High-tech Zone Meinuo Pharmaceutical Innovation Research Institute, impacting the consolidated financial statements[6].